title: Withdrawal of steroids from triple-drug therapy in kidney transplant patients.
abstract: BACKGROUND
  In renal transplant patients with stable graft function, triple-drug immunosuppression may not be necessary, while withdrawal of steroids may eliminate side effects. The primary aim of this study was to assess the risk of rejection after steroid withdrawal.
  
  
  METHODS
  A total of 88 patients with stable graft function and serum creatinine <160 micromol/l, treated with cyclosporin A, azathioprine and prednisone were randomized into group A (n=46) with a gradual prednisone reduction to zero in the course of 6 months, and group B (n=42) on triple-drug therapy without change. At the time of randomization, fine-needle aspiration biopsy (FNAB) was carried out in all of the patients. After stopping steroids, the patients were followed up for a period of 12 months.
  
  
  RESULTS
  Four patients failed to complete steroid withdrawal, three due to rejection, and one due to leukopenia. The proportion of rejection in three patients in group A (6.6%) was not significantly different from rejection in two patients in group B (4.8%). The mean value of serum creatinine was not significantly different in both groups in the course of follow-up. A finding of some degree of immunological activity in FNAB was made in four patients in each group, but none of these patients developed rejection. Compared with group B, significant decreases in serum cholesterol and blood leukocytes were observed in group A. Prednisone withdrawal did not have any influence on hypertension and serum triglycerides.
  
  
  CONCLUSIONS
  Gradual withdrawal of steroids is not associated with a higher risk for rejection and has a beneficial effect on serum total cholesterol levels. FNAB was not a useful tool for predicting rejection.
authors.affiliation: Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: I
authors.initials: I
authors.lastname: Matl
authors.forename: J
authors.initials: J
authors.lastname: Lácha
authors.forename: A
authors.initials: A
authors.lastname: Lodererová
authors.forename: M
authors.initials: M
authors.lastname: Símová
authors.forename: V
authors.initials: V
authors.lastname: Teplan
authors.forename: V
authors.initials: V
authors.lastname: Lánská
authors.forename: S
authors.initials: S
authors.lastname: Vítko
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage* / Q000627:therapeutic use; D001707:Biopsy, Needle; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011241:Prednisone / Q000008:administration & dosage* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D002784:Cholesterol; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone